Patents by Inventor Daniel Zewge

Daniel Zewge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10738308
    Abstract: The present invention relates to RNAi molecules, and compositions thereof, comprising a 2? internucleoside linkage connecting the nucleotide at position 1 and the nucleotide at position 2 at the 5? end of the antisense strand. Specifically, the invention relates to single- and double-stranded short interfering nucleic acid (siNA) molecules that are capable of mediating RNA interference comprising 5? modified nucleotides that comprise, among other potential modifications, a 2? internucleoside linkage. The invention further relates to 5? modified nucleotides used as reagents to generate the RNAi molecules of the invention and methods of using the disclosed RNAi molecules.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: August 11, 2020
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Wonsuk Chang, Erin N. Guidry, Matthew G. Stanton, Daniel Zewge
  • Patent number: 10550385
    Abstract: This invention relates to a process for introducing two or more 2?-modifications into an RNA, wherein the RNA has a 2?-O substituent containing an alkyl ester functional group on one or more ribose rings of a strand and a 2?-O substituent containing an alkyne functional groups on one or more ribose rings on the same strand. The process comprises a) adding an amine compound to the RNA to form amidation reactions with the alkyl ester functional groups; b) dissolving the modified RNA from step (a) in a solvent to form a solution; and c) adding an organic azide and a copper or ruthenium catalyst to the solution obtained in step (b) to form 2?-azide-alkyne cycloaddition reaction products with the alkyne functional groups.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: February 4, 2020
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Daniel Zewge, Gregory T. Copeland, Zhen Li, Joseph D. Armstrong
  • Publication number: 20180265869
    Abstract: The present invention relates to RNAi molecules, and compositions thereof, comprising a 2? internucleoside linkage connecting the nucleotide at position 1 and the nucleotide at position 2 at the 5? end of the antisense strand. Specifically, the invention relates to single- and double-stranded short interfering nucleic acid (siNA) molecules that are capable of mediating RNA interference comprising 5? modified nucleotides that comprise, among other potential modifications, a 2? internucleoside linkage. The invention further relates to 5? modified nucleotides used as reagents to generate the RNAi molecules of the invention and methods of using the disclosed RNAi molecules.
    Type: Application
    Filed: January 5, 2018
    Publication date: September 20, 2018
    Inventors: Wonsuk Chang, Erin N. Guidry, Matthew G. Stanton, Daniel Zewge
  • Patent number: 9896688
    Abstract: The present invention relates to RNAi molecules, and compositions thereof, comprising a 2? internucleoside linkage connecting the nucleotide at position 1 and the nucleotide at position 2 at the 5? end of the antisense strand. Specifically, the invention relates to single- and double-stranded short interfering nucleic acid (siNA) molecules that are capable of mediating RNA interference comprising 5? modified nucleotides that comprise, among other potential modifications, a 2? internucleoside linkage. The invention further relates to 5? modified nucleotides used as reagents to generate the RNAi molecules of the invention and methods of using the disclosed RNAi molecules.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: February 20, 2018
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Wonsuk Chang, Erin N. Guidry, Matthew G. Stanton, Daniel Zewge
  • Publication number: 20170137815
    Abstract: In an embodiment the instant invention discloses a modular composition comprising 1) an oligonucleotide; 2) one or more linkers, which may be the same or different, selected from Table 1, wherein the linkers are attached to the oligonucleotide at the 2?-position of the ribose rings and/or the terminal 3?- and/or 5?-positions of the oligonucleotide; 3) optionally, one or more peptides, which may be the same or different, selected from SEQ ID NOs: 1-59, wherein the peptides are attached to the linkers; and optionally one or more lipids, solubilizing groups and/or targeting ligands attached to the oligonucleotide.
    Type: Application
    Filed: January 19, 2017
    Publication date: May 18, 2017
    Inventors: Steven L. COLLETTI, Francis GOSSELIN, Vasant R. JADHAV, Anthony W. SHAW, David M. TELLERS, Thomas J. TUCKER, Yu YUAN, Daniel ZEWGE
  • Publication number: 20160348109
    Abstract: This invention relates to a 2?-modified RNA agent comprising at least one RNA strand containing a 2?-O substituent having an alkyne functional group attaching to the O atom at the 2?-position on one or more ribose rings, wherein the 2?-O substituent is located at one or more of positions 2, 3, 4, 7, 8, 9, 10, 11, 13, 14, and 16, from 5?-end of the RNA strand. This invention also relates to a 2?-modified RNA agent comprising at least one RNA strand containing a 2?-O substituent having a triazole functional group attaching to the O atom at the 2?-position on one or more ribose rings, wherein the 2?-O substituent is located at one or more of positions 2, 3, 4, 7, 8, 9, 10, 11, 13, 14, and 16, from 5?-end of the RNA strand.
    Type: Application
    Filed: August 11, 2016
    Publication date: December 1, 2016
    Inventors: Daniel ZEWGE, Francis GOSSELIN
  • Patent number: 9441228
    Abstract: This invention relates to a 2?-modified RNA agent comprising at least one RNA strand containing a 2?-O substituent having an alkyne functional group attaching to the O atom at the 2?-position on one or more ribose rings, wherein the 2?-O substituent is located at one or more of positions 2, 3, 4, 7, 8, 9, 10, 11, 13, 14, and 16, from 5?-end of the RNA strand. This invention also relates to a 2?-modified RNA agent comprising at least one RNA strand containing a 2?-O substituent having a triazole functional group attaching to the O atom at the 2?-position on one or more ribose rings, wherein the 2?-O substituent is located at one or more of positions 2, 3, 4, 7, 8, 9, 10, 11, 13, 14, and 16, from 5?-end of the RNA strand.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: September 13, 2016
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Daniel Zewge, Francis Gosselin
  • Publication number: 20160074525
    Abstract: In an embodiment the instant invention discloses a modular composition comprising 1) an oligonucleotide; 2) one or more linkers, which may be the same or different, selected from Table 1, wherein the linkers are attached to the oligonucleotide at the 2?-position of the ribose rings and/or the terminal 3?- and/or 5?-positions of the oligonucleotide; 3) optionally, one or more peptides, which may be the same or different, selected from SEQ ID NOs: 1-59, wherein the peptides are attached to the linkers; and optionally one or more lipids, solubilizing groups and/or targeting ligands attached to the oligonucleotide.
    Type: Application
    Filed: September 8, 2015
    Publication date: March 17, 2016
    Inventors: Steven L. COLLETTI, Francis GOSSELIN, Vasant R. JADHAV, Anthony W. SHAW, David M. TELLERS, Thomas J. TUCKER, Yu YUAN, Daniel ZEWGE
  • Publication number: 20160068837
    Abstract: The present invention relates to RNAi molecules, and compositions thereof, comprising a 2? internucleoside linkage connecting the nucleotide at position 1 and the nucleotide at position 2 at the 5? end of the antisense strand. Specifically, the invention relates to single- and double-stranded short interfering nucleic acid (siNA) molecules that are capable of mediating RNA interference comprising 5? modified nucleotides that comprise, among other potential modifications, a 2? internucleoside linkage. The invention further relates to 5? modified nucleotides used as reagents to generate the RNAi molecules of the invention and methods of using the disclosed RNAi molecules.
    Type: Application
    Filed: February 20, 2014
    Publication date: March 10, 2016
    Applicant: SIRNA THERAPEUTICS, INC.
    Inventors: Wonsuk Chang, Erin N. Guidry, Matthew G. Stanton, Daniel Zewge
  • Publication number: 20150322433
    Abstract: This invention relates to the post-synthetic chemical modifications of RNA at the 2?-position on the ribose rings via orthogonal chemistry involving amidation reactions plus metal catalyzed alkyne-azide cycloaddition (click) reactions.
    Type: Application
    Filed: December 18, 2013
    Publication date: November 12, 2015
    Applicant: SIRNA THERAPEUTICS, INC.
    Inventors: Daniel Zewge, Gregory T. Copeland, Zhen LI, Joseph D. Armstrong
  • Publication number: 20150211008
    Abstract: This invention relates to the post-synthetic chemical modification of RNA at the 2?-position on the ribose ring via a copper catalyzed Huisgen cycloaddition (“click” chemistry: Kolb, Sharpless Drug Discovery Today 2003, 8, 1128). The invention 1) avoids complex, tedious multi-step syntheses of each desired modified ribonucleoside; 2) allows diverse chemical modifications using high-fidelity chemistry that is completely orthogonal to commonly used alkylamino, carboxylate and disulfide linker reactivities; 3) allows introduction of functional groups that are incompatible with modern automated solid-phase synthesis of RNA and subsequent cleavage-deprotection steps; 4) allows introduction of functional groups useful as targeting ligands; and 5) enables high-throughput structure-activity relationship studies on chemically modified RNA in 96-well format.
    Type: Application
    Filed: January 29, 2015
    Publication date: July 30, 2015
    Inventors: Daniel ZEWGE, Francis GOSSELIN
  • Publication number: 20130253168
    Abstract: In an embodiment the instant invention discloses a modular composition comprising 1) an oligonueleotide; 2) one or more linkers, which may be the same or different, selected from Table 1, wherein the linkers are attached to the oligonucleotide at the 2?-position of the ribose rings and/or the terminal 3?- and/or 5?-positions of the oligonucleotide; 3) optionally, one or more peptides, which may be the same or different, selected from SEQ ID NOs: 1-59, wherein the peptides are attached to the linkers; and optionally one or more lipids, solubilizing groups and/or targeting ligands attached to the oligonucleotide.
    Type: Application
    Filed: August 29, 2011
    Publication date: September 26, 2013
    Inventors: Steven L. Colletti, Francis Gosselin, Vasant R. Jadhav, Anthony W. Shaw, David M. Tellers, Thomas J. Tucker, Yu Yuan, Daniel Zewge
  • Publication number: 20130116419
    Abstract: This invention relates to the post-synthetic chemical modification of RNA at the 2?-position on the ribose ring via a copper catalyzed Huisgen cycloaddition (“click” chemistry: Kolb, Sharpless Drug Discovery Today 2003, 8, 1128). The invention 1) avoids complex, tedious multi-step syntheses of each desired modified ribonucleoside; 2) allows diverse chemical modifications using high-fidelity chemistry that is completely orthogonal to commonly used alkylamino, carboxylate and disulfide linker reactivities; 3) allows introduction of functional groups that are incompatible with modern automated solid-phase synthesis of RNA and subsequent cleavage-deprotection steps; 4) allows introduction of functional groups useful as targeting ligands; and 5) enables high-throughput structure-activity relationship studies on chemically modified RNA in 96-well format.
    Type: Application
    Filed: January 19, 2011
    Publication date: May 9, 2013
    Inventors: Daniel Zewge, Francis Gosselin